Statement from CPRIT CEO Wayne Roberts on Passage of Proposition 6

Texans set a course in 2007 to conquer cancer. Yesterday’s vote underscores the state’s unprecedented commitment to improve the health and lives of our fellow Texans by preventing, treating, and curing cancer. Everyone at CPRIT appreciates the confidence Texans place in us to guide the state toward a cancer-free future.

The Texas-Israel Alliance Healthcare Innovation Conference

CPRIT is a proud partner with the Texas-Israel Alliance at the Texas-Israel Alliance Healthcare Innovation Conference October 25, 2019.

Cancer Prevention & Research Institute of Texas Awards $136 Million in New Grants

AUSTIN — The Cancer Prevention and Research Institute of Texas (CPRIT) today awarded 71 new grants totaling close to $136 million to advance the fight against cancer. This total includes 58 academic research grant awards, 10 prevention awards, and 3 product development research awards.

“CPRIT’s priorities of pediatric cancer research and cancers of significance to Texans highlight this large slate of awards,” said Wayne Roberts, CPRIT Chief Executive Officer. “Investments are made across the cancer research and prevention continuum in Texas unlike any other state in the country.”

Cancer Prevention & Research Institute of Texas Awards $6 Million in New Grants to the Texas Tech University System

AUSTIN — The Cancer Prevention and Research Institute of Texas (CPRIT) today awarded four new grants to the Texas Tech University System totaling over $6 million.

“This round of awards emphasizes CPRIT’s priorities of pediatric cancer prevention and research, reaching underserved populations and investing in early translational research,” said Wayne Roberts, CPRIT Chief Executive Officer. “The world-class institutions of the Texas Tech University System are conducting important work in cancer research and prevention, addressing cancers of importance and delivering vital services directly to Texans.”

CPRIT and Salarius Pharmaceuticals

CPRIT makes childhood cancer a priority with 12% of its portfolio going to childhood cancer research — proportionately 3 times more than the national commitment. ​Ewing’s Sarcoma is a rare and devastating bone and soft-tissue cancer that mostly afflicts children and young adults for which no approved targeted therapies are currently available.

CPRIT and Hummingbird Bioscience

CPRIT is participating in BIO 2019 this week in Philadelphia with over 16,000 attendees representing the biotech and pharma industry from around the world. We will be educating them on funding opportunities for CPRIT’s Product Development Research program which is currently accepting applications for our Company Relocation Awards, Texas Company Awards, and Seed Awards.